RCT Treatment Versus Non Treatment of Low-risk BCCs in Elderly (BASINEL)

A Large Pragmatic RCT Investigating Treatment Versus Non Treatment of Low-risk BCCs in Elderly

This study will be a randomized controlled trial (RCT). Patients with a minimum age of 75 years who consult at the dermatology department of the Ghent University Hospital and who are diagnosed with minimum one lesion suspicious for a low-risk basal cell carcinoma will be asked to participate in this study.

Rationale: Basal cell carcinomas (BCCs) represent 70% of all skin cancers. These tumors do not metastasize but are locally invasive if left untreated. There is a high incidence of BCC in elderly and clinicians frequently face important treatment dilemmas. The approach to BCC in elderly should be investigated thoroughly, since current data on health-related quality of life, complication risks and biological behavior of these tumors is absent, and most guidelines are based on studies in young patients.

Objective: The investigators will examine the possibility of not treating all BCCs by collecting data on the in vivo biological behavior of low-risk basal cell carcinomas in elderly patients with state-of-the-art imaging techniques. The investigators want to combine tumor characteristics with patient profiles, in order to estimate whether a chosen treatment will positively affect the patients' quality of life within a predetermined timeframe.

Study design: Randomized controlled trial (RCT) with study visits every 6 to 12 months for a total follow-up period of 36 months.

Study population: Patients consulting at the Department of Dermatology of the Ghent University Hospital with the minimum age of 75 years and a new diagnosis of (a) low-risk basal cell carcinoma(s).

Intervention: Evaluation of the impact on the quality of life and the complication risks in both study arms. In addition, survival data will be gathered in both study arms. In the non-treatment arm, there will be an evaluation of the biological behavior of these low-risk basal cell carcinomas using in vivo imaging devices.

Patients in the treatment arm will receive standard care. Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices. Patients will be asked to fill in a questionnaire concerning their HrQoL at consecutive time points. Also patient-reported side effects will be evaluated via a questionnaire. The investigators will compare standard treatment versus non-treatment (1:1 allocation) in a randomized controlled trial.

Subjects can withdraw from participating in this study at any time for any reason without any consequences.

Study Overview

• Status: Recruiting
• Conditions: Elderly; Basal Cell Carcinoma
• Intervention / Treatment: Other: Standard of care; Other: Monitoring

Detailed Description

See protocol

• Study Type: Interventional
• Enrollment (Estimated): 280
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Laura Van Coile, MD; Phone Number: +3293322287; Email: laura.vancoile@uzgent.be
• Study Contact Backup: Name: Isabelle Hoorens, MD, PhD; Phone Number: +3293322287; Email: isabelle.hoorens@uzgent.be

Study Locations

• Belgium
  • East Flanders
    • Ghent, East Flanders, Belgium, 9000
      • Recruiting
      • Department of Dermatology, Ghent University Hospital
      • Contact: Laura Van Coile, MD; Phone Number: +3293322287; Email: laura.vancoile@uzgent.be
      • Contact: Isabelle Hoorens, MD, PhD; Phone Number: +3293322287; Email: isabelle.hoorens@uzgent.be
      • Principal Investigator: Lieve Brochez, MD, PhD
      • Sub-Investigator: Evelien Verhaeghe, MD, PhD
      • Sub-Investigator: Katia Ongenae, MD, PhD
      • Sub-Investigator: Amber Shen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 75 years and older (Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

- Patients with the age of 75 years or older with a new diagnosis of at least one basal cell carcinoma localized on the trunk or on the limbs (with the exception of BCCs on the hands and/or the feet).

Exclusion Criteria:

• Patient is unable to provide consent.
• Patient is unable to understand the task and questionnaires.
• Patient is immunocompromised.
• Patient has a genetic skin cancer syndrome.
• The BCC has a diameter of more than 3 cm.
• The BCC occurs in a skin site that underwent radiotherapy in the past.
• Patient is being treated with chemoprevention for KC or underwent a recent field treatment for KC in the region of the low-risk BCC.
• Patient has a history of malignant melanoma or other types of NMSC (with the exception of KC).
• Patient has had a high-risk SCC during the last 2 years or a SCC in the head and neck region during the last 2 years.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Treatment arm (T-arm); Patients in the T-arm will receive diagnostic investigation(s) as in standard care. This includes clinical and dermoscopic examination and (in most cases) a biopsy to confirm the diagnosis of a BCC. Patients will be asked to fill out a questionnaire (Q) concerning their HrQoL. Important is the possible exclusion of patients (when the biopsy shows the lesion is not a BCC) in this step. Patients will receive treatment of their BCC in accordance with the standard treatment regimen. The treatment will be performed by an independent dermatologist of the investigator's department who is blinded and not aware of the patient's participation in this study. After the treatment, a new Q will be sent out to capture the HrQoL and possible patient-reported side effects. Afterwards, the patients will be followed every 6 to 12 months for 36 months with a clinical evaluation of the previously treated skin site, evaluation of possible complications and the HrQoL and complications Qs.	Other: Standard of care; Patients in the treatment arm will receive standard care.
Other: non-Treatment arm (n-T-arm); Patients allocated to the n-T-arm will receive diagnostic investigations by non-invasive imaging techniques to confirm the diagnosis of a BCC. Patients will be asked to fill out a Q concerning their HrQoL. Important to point out is the possible exclusion of certain patients (when the imaging shows the lesion is not a BCC) in this step. The patients in this arm will be followed every 6 to 12 months for 36 months. Every study visit there will be a clinical evaluation of the tumor. At the follow-up visits of 6, 12, 24 and 36 months a new documentation of the tumor will take place with in vivo imaging. At these time-points, patients will also be asked to fill out the HrQoL Q and complications Q. Because of ethical reasons, a maximum tolerable diameter of the tumor has been defined in advance: BCCs in the non-treatment arm that reach a diameter of 4cm will be excluded and will receive treatment.	Other: Monitoring; Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices based on multispectral dermoscopy, reflectance confocal microscopy to determine the exact histology and high definition optical coherence tomography for imaging and volume calculation of the BCC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Health-related Quality of Life	To determine the impact on the health-related quality of life in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Day 0
Health-related Quality of Life	To determine the impact on the health-related quality of life in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Day of Treatment
Health-related Quality of Life	To determine the impact on the health-related quality of life in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Month 6
Health-related Quality of Life	To determine the impact on the health-related quality of life in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Month 12
Health-related Quality of Life	To determine the impact on the health-related quality of life in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Month 24
Health-related Quality of Life	To determine the impact on the health-related quality of life in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Month 36
Complication risks	To determine the complication risk in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Day of Treatment
Complication risks	To determine the complication risk in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Month 6
Complication risks	To determine the complication risk in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Month 12
Complication risks	To determine the complication risk in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Month 24
Complication risks	To determine the complication risk in elderly patients with low-risk basal cell carcinomas in the treatment versus the non-treatment arm.	Month 36

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survival	To determine the survival of elderly patients with low-risk basal cell carcinoma in the treatment versus the non-treatment arm.	Month 36 + 10 years
Natural behavior	To evaluate the in vivo natural behavior and growth of the basal cell carcinomas in the non-treatment arm.	Day 0
Natural behavior	To evaluate the in vivo natural behavior and growth of the basal cell carcinomas in the non-treatment arm.	Month 6
Natural behavior	To evaluate the in vivo natural behavior and growth of the basal cell carcinomas in the non-treatment arm.	Month 12
Natural behavior	To evaluate the in vivo natural behavior and growth of the basal cell carcinomas in the non-treatment arm.	Month 24
Natural behavior	To evaluate the in vivo natural behavior and growth of the basal cell carcinomas in the non-treatment arm.	Month 36

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment effectiveness	To determine treatment effectiveness (recurrence rates of the BCCs after 36 months) of the different (standard of care) therapies administered in the treatment arm.	Month 36

Collaborators and Investigators

• Sponsor: University Hospital, Ghent
• Investigators: Principal Investigator: Lieve Brochez, MD, PhD, Ghent University Hospital, Department of Dermatology

Publications and helpful links

General Publications

• Van Coile L, Verhaeghe E, Ongenae K, Brochez L, Hoorens I. Study protocol of the BASINEL Study: a pragmatic randomised controlled trial investigating treatment versus no treatment of low-risk basal cell carcinomas in older persons. BMJ Open. 2022 Nov 10;12(11):e063526. doi: 10.1136/bmjopen-2022-063526.

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2021
• Primary Completion (Estimated): October 31, 2026
• Study Completion (Estimated): October 31, 2026

Study Registration Dates

• First Submitted: October 14, 2021
• First Submitted That Met QC Criteria: October 28, 2021
• First Posted (Actual): November 8, 2021

Study Record Updates

• Last Update Posted (Actual): December 8, 2023
• Last Update Submitted That Met QC Criteria: December 7, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: Active surveillance; Watchful waiting
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Basal Cell; Carcinoma, Basal Cell
• Other Study ID Numbers: BASINEL

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No